Your browser is no longer supported. Please, upgrade your browser.
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E41.07 EPS (ttm)2.83 Insider Own0.10% Shs Outstand1.77B Perf Week-1.60%
Market Cap209.95B Forward P/E8.35 EPS next Y13.92 Insider Trans-15.18% Shs Float1.76B Perf Month3.25%
Income5.08B PEG9.13 EPS next Q3.23 Inst Own69.00% Short Float0.83% Perf Quarter4.30%
Sales50.20B P/S4.18 EPS this Y-48.50% Inst Trans0.26% Short Ratio2.33 Perf Half Y13.49%
Book/sh7.75 P/B15.01 EPS next Y10.61% ROA3.00% Target Price124.08 Perf Year21.10%
Cash/sh5.42 P/C21.47 EPS next 5Y4.50% ROE32.10% 52W Range79.11 - 119.13 Perf YTD8.54%
Dividend5.20 P/FCF23.14 EPS past 5Y-2.80% ROI12.70% 52W High-2.38% Beta0.80
Dividend %4.47% Quick Ratio0.70 Sales past 5Y14.90% Gross Margin64.90% 52W Low47.01% ATR1.68
Employees48000 Current Ratio0.80 Sales Q/Q50.90% Oper. Margin22.60% RSI (14)48.93 Volatility1.44% 1.38%
OptionableYes Debt/Eq6.24 EPS Q/Q6.50% Profit Margin9.10% Rel Volume1.41 Prev Close118.87
ShortableYes LT Debt/Eq5.41 EarningsJul 30 BMO Payout173.80% Avg Volume6.30M Price116.30
Recom2.00 SMA20-0.59% SMA500.91% SMA2008.63% Volume9,017,218 Change-2.16%
Jul-27-21Resumed Truist Buy $118
Apr-07-21Resumed RBC Capital Mkts Outperform $135
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
Aug-01-21 07:01AM  
Jul-31-21 12:31AM  
Jul-30-21 04:23PM  
11:40AM  
10:14AM  
10:12AM  
09:35AM  
09:05AM  
08:57AM  
08:50AM  
08:19AM  
08:17AM  
07:49AM  
07:46AM  
07:44AM  
04:01AM  
Jul-29-21 11:09AM  
10:35AM  
09:07AM  
08:31AM  
08:30AM  
02:22AM  
Jul-28-21 02:47PM  
12:48PM  
10:25AM  
09:59AM  
08:07AM  
Jul-27-21 07:35PM  
03:56PM  
12:06PM  
11:32AM  
09:26AM  
08:30AM  
Jul-26-21 05:45PM  
10:12AM  
05:52AM  
Jul-25-21 09:57PM  
11:31AM  
05:55AM  
Jul-24-21 06:04AM  
Jul-23-21 04:47PM  
03:00PM  
02:57PM  
01:11PM  
12:37PM  
12:10PM  
08:01AM  
Jul-22-21 03:20PM  
12:46PM  
11:10AM  
10:37AM  
10:06AM  
07:06AM  
06:31AM  
Jul-21-21 11:45AM  
10:55AM  
10:16AM  
01:00AM  
Jul-20-21 02:53PM  
08:30AM  
Jul-19-21 05:45PM  
11:16AM  
10:31AM  
Jul-18-21 09:01AM  
Jul-16-21 01:57PM  
12:10PM  
11:48AM  
08:30AM  
Jul-14-21 12:57PM  
08:42AM  
06:02AM  
Jul-13-21 02:07PM  
11:52AM  
09:15AM  
Jul-12-21 05:45PM  
03:00PM  
10:04AM  
Jul-10-21 03:02AM  
Jul-09-21 04:02PM  
12:41AM  
Jul-08-21 04:06PM  
Jul-07-21 08:55AM  
08:39AM  
08:00AM  
06:10AM  
Jul-06-21 04:47PM  
09:39AM  
05:55AM  
Jul-05-21 05:45PM  
11:45AM  
11:40AM  
11:30AM  
05:55AM  
Jul-03-21 06:04AM  
Jul-02-21 08:06AM  
05:52AM  
Jul-01-21 02:16PM  
Jun-30-21 01:42PM  
10:45AM  
Jun-29-21 08:00AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SALEKI-GERHARDT AZITAEVP, OperationsMay 24Option Exercise34.9386,9203,036,230203,204May 26 05:20 PM
SALEKI-GERHARDT AZITAEVP, OperationsMay 24Sale116.2986,92010,108,033116,284May 26 05:20 PM
Strom Carrie CSVP & Pres Global Allerg AesthMay 03Option Exercise41.394,184173,17663,409May 05 04:23 PM
Strom Carrie CSVP & Pres Global Allerg AesthMay 03Sale112.404,184470,28259,225May 05 04:23 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 02Option Exercise54.86170,1139,332,399546,710Mar 02 08:27 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 01Sale108.61170,11318,476,204376,597Mar 02 08:27 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMar 01Sale108.5913,7731,495,57650,969Mar 02 08:26 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMar 01Sale108.5919,5142,119,0410Mar 02 08:31 PM
Sorg Elaine K.SVP, US Commercial OperationsMar 01Sale108.618,440916,64217,595Mar 02 08:30 PM
Sorg Elaine K.SVP, US Commercial OperationsFeb 22Option Exercise89.7820,1951,813,05252,946Feb 24 06:28 PM
Sorg Elaine K.SVP, US Commercial OperationsFeb 22Sale104.7220,1952,114,73232,751Feb 24 06:28 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Option Exercise51.4225,2901,300,41276,259Dec 31 01:15 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Sale105.0025,2902,655,45050,969Dec 31 01:15 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Option Exercise51.4251,9902,673,32651,990Dec 01 05:22 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Sale105.0051,9905,458,9500Dec 01 05:22 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 20Sale99.3840,0003,975,04620,006Nov 24 05:34 PM
ALBAN CARLOSVice ChairmanNov 16Option Exercise35.88115,8304,155,980230,729Nov 18 05:04 PM
ALBAN CARLOSVice ChairmanNov 16Sale100.00115,83011,583,000114,899Nov 18 05:04 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Option Exercise57.12194,15411,089,858512,796Nov 12 05:54 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Sale97.10194,15418,851,790318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 10Sale98.0017,4261,707,74896,441Nov 12 05:56 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 09Sale95.7437,4503,585,463318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 04Sale93.614,800449,328109,067Nov 06 04:29 PM
SEVERINO MICHAELVice ChairmanNov 04Sale93.6190,6798,488,46167,281Nov 06 04:29 PM